Cargando…

Abdominal Pain Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea

Abdominal pain is the principal symptom of irritable bowel syndrome (IBS). This analysis examined abdominal pain response in adults with IBS with diarrhea (IBS-D) receiving the nonsystemic antibiotic rifaximin. METHODS: In the Targeted Nonsystemic Antibiotic Rifaximin Gut-Selective Evaluation of Tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lembo, Anthony, Rao, Satish S. C., Heimanson, Zeev, Pimentel, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7145050/ https://www.ncbi.nlm.nih.gov/pubmed/32352714 http://dx.doi.org/10.14309/ctg.0000000000000144

Ejemplares similares

Lactulose Breath Testing as a Predictor of Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea
por: Rezaie, Ali, et al.
Publicado: (2019)

Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial
por: Cash, Brooks D., et al.
Publicado: (2017)

Rifaximin Therapy of Irritable Bowel Syndrome
por: Koo, Hoonmo L., et al.
Publicado: (2012)

Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity
por: Pimentel, M., et al.
Publicado: (2017)

Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome
por: Fodor, Anthony A., et al.
Publicado: (2018)

Antimicrobial Susceptibility of Staphylococcus Isolates from the Skin of Patients with Diarrhea-Predominant Irritable Bowel Syndrome Treated with Repeat Courses of Rifaximin
por: DuPont, Herbert L., et al.
Publicado: (2016)

Rifaximin has the potential to prevent complications of cirrhosis
por: Flamm, Steven L., et al.
Publicado: (2018)

Cognition of abdominal pain and abdominal discomfort in Chinese patients with irritable bowel syndrome with diarrhea
por: Lu, Jia, et al.
Publicado: (2023)

Profile of rifaximin and its potential in the treatment of irritable bowel syndrome
por: Iorio, Natalya, et al.
Publicado: (2015)

Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double‐blind, placebo‐controlled trials
por: Schoenfeld, P., et al.
Publicado: (2014)

Capsule Endoscopy in Refractory Diarrhea-Predominant Irritable Bowel Syndrome and Functional Abdominal Pain
por: Valero, Manuel, et al.
Publicado: (2018)

Development and Validation of a Biomarker for Diarrhea-Predominant Irritable Bowel Syndrome in Human Subjects
por: Pimentel, Mark, et al.
Publicado: (2015)

Short-course therapy for diarrhea-predominant irritable bowel syndrome: understanding the mechanism, impact on gut microbiota, and safety and tolerability of rifaximin
por: Chang, Christopher
Publicado: (2018)

Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome
por: Zhuang, Xiaojun, et al.
Publicado: (2020)

High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome
por: Jolley, John
Publicado: (2011)

Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome
por: Boltin, Doron, et al.
Publicado: (2014)

Effects of Rifaximin on Transit, Permeability, Fecal Microbiome, and Organic Acid Excretion in Irritable Bowel Syndrome
por: Acosta, Andrés, et al.
Publicado: (2016)

Rifaximin for Irritable Bowel Syndrome: A Meta-Analysis of Randomized Placebo-Controlled Trials
por: Li, Jun, et al.
Publicado: (2016)

Irritable bowel syndrome and diet
por: Portincasa, Piero, et al.
Publicado: (2017)

Review of Rifaximin: Latest Treatment Frontier for Irritable Bowel Syndrome Mechanism of Action and Clinical Profile
por: Gupta, Kamesh, et al.
Publicado: (2017)

Mechanism of action and therapeutic benefit of rifaximin in patients with irritable bowel syndrome: a narrative review
por: Chey, William D., et al.
Publicado: (2020)

Randomized Clinical Trial: Crofelemer Treatment in Women With Diarrhea-Predominant Irritable Bowel Syndrome
por: Nee, Judy, et al.
Publicado: (2019)

Chronic bacterial prostatitis and irritable bowel syndrome: effectiveness of treatment with rifaximin followed by the probiotic VSL#3
por: Vicari, Enzo, et al.
Publicado: (2014)

Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome
por: Zeber-Lubecka, Natalia, et al.
Publicado: (2016)

Biomarkers of Irritable Bowel Syndrome
por: Kim, Jae Hak, et al.
Publicado: (2017)

Evaluation of the irritable bowel syndrome severity index in Japanese male patients with irritable bowel syndrome with diarrhea
por: Ida, Motoko, et al.
Publicado: (2017)

Targeted therapies for diarrhea-predominant irritable bowel syndrome
por: Olden, Kevin W
Publicado: (2012)

Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome
por: Lacy, Brian E
Publicado: (2016)

Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome
por: Özdener, Ayşe Elif, et al.
Publicado: (2017)

Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea
por: Cash, Brooks D, et al.
Publicado: (2017)

Determination of Rifaximin Treatment Period According to Lactulose Breath Test Values in Nonconstipated Irritable Bowel Syndrome Subjects
por: Bae, Suhyun, et al.
Publicado: (2015)

Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach
por: Soldi, Sara, et al.
Publicado: (2015)

Does rifaximin offer any promise in Crohn's disease in remission and concurrent irritable bowel syndrome-like symptoms?
por: Tocia, Cristina, et al.
Publicado: (2021)

Effectiveness of Rifaximin on the Outcomes of Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Khan, Zarghuna, et al.
Publicado: (2023)

Symptom Severity Following Rifaximin and the Probiotic VSL#3 in Patients with Chronic Pelvic Pain Syndrome (Due to Inflammatory Prostatitis) Plus Irritable Bowel Syndrome
por: Vicari, Enzo, et al.
Publicado: (2017)

Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea
por: Fragkos, Konstantinos C
Publicado: (2017)

Misinterpreting Diarrhea-Predominant Irritable Bowel Syndrome and Functional Diarrhea: Pathophysiological Highlights
por: Sciumè, Giusi Desirè, et al.
Publicado: (2023)

Fungal feelings in the irritable bowel syndrome: the intestinal mycobiome and abdominal pain
por: van Thiel, Iam, et al.
Publicado: (2023)

Genotypes of Pain and Analgesia in a Randomized Trial of Irritable Bowel Syndrome
por: Vollert, Jan, et al.
Publicado: (2022)

Qualitative Development of a Patient-Reported Outcome Symptom Measure in Diarrhea-Predominant Irritable Bowel Syndrome
por: Marquis, P, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ajf5h35ef4hei1r57tvc18g03f